ALPEGA-GROUP
27.3.2020 13:07:08 CET | Business Wire | Press release
In response to the coronavirus crisis, Teleroute invites transport and logistics companies to join its community free of charge till the end of June.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200327005212/en/
In normal times, more than 200,000 daily freight and vehicle offers are posted on Teleroute . However, the COVID-19 pandemic has led to a drastic increase in the volume of goods required by sectors like retail and pharma. All of this is putting the response capacity of the transport and logistics sector, whose role is key to the management of this crisis, to the test.
For this reason, the Teleroute Freight Exchange , part of the Alpega Group , wants to help alleviate the situation by offering free access to all transport and logistics companies that wish to join its platform, till the end of June and without any contractual obligation to prolong.
About this initiative, Fabrice Douteaud , Chief Operation Officer Freight Exchange, comments: “We feel it is our responsibility to help society in all possible ways during this difficult period. Hence, we are joining the wave of solidarity by significantly enlarging our transport community with these temporary measures and contribute to overcoming the logistic challenges that we are facing with COVID-19. By spreading the word about this initiative, all of us can support in further shaping transport collaboration.”
All the security guarantees offered by Teleroute, such as its Quality Assurance Policy in accepting new members or the recently announced Payment Guarantee , remain unchanged, as the main objective is to continue providing the industry with the best possible collaboration network at a time when cooperation between companies is more necessary than ever. Securing the safety of the platform therefore remains a number one priority.
The freight exchanges were born to achieve greater efficiency in transport and to bring the different actors in the sector together. Now, it is up to all of us to create a stronger transport network that remains united in times like these. #Allinthistogether
About Alpega
The Alpega Group is a leading global logistics software company offering end-to-end solutions that cover all transportation needs, including Transport Management Systems (TMS) and Freight Exchanges. The Transport Management Systems (TMS) software solutions – inet and Transwide– connect companies to a broad network of logistics providers and digitize their complex supply chain management. These systems provide live visibility of incoming and outgoing logistics and seamlessly link truck drivers and logistics providers with shippers. The freight exchanges – Teleroute, Wtransnet, Bursa and 123cargo – serve as marketplaces for matching spot shipments and capacities. TenderEasy, for its part, allows shippers to easily send e-tenders to the carrier community. All of the above solutions can be combined to create more added value for customers. Our user community of 80.000 carriers and shippers and 200.000 members are electronically connected every day to successfully manage critical transport processes of 108.000.000 orders every year. Alpega is present in 80 countries worldwide and employs over 500 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
